When was QV Bioelectronics founded?

QV Bioelectronics was founded in 2019 and raised its 1st funding round within a year of its incorporation.

Where is QV Bioelectronics located?

QV Bioelectronics is headquartered in Manchester, United Kingdom. It is registered at 1F70 MERESIDE,ALDERLEY PARK,NETHER ALDERLEY,CHESHIRE,ENGLAND,SK10 4TG.

Who is the current CEO of QV Bioelectronics?

Christopher Bullock and Carl Daintree s of QV Bioelectronics. Christopher Bullock has also founded 2 companies.

Which legal entities is QV Bioelectronics associated with?

QV Bioelectronics is associated with QV BIOELECTRONICS LTD and 1 other.

How many employees does QV Bioelectronics have?

As of Aug 31, 2026, the latest employee count at QV Bioelectronics is 18.

Is QV Bioelectronics a funded company?

QV Bioelectronics is a funded company, having raised a total of $9.63M across 6 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Oct 29, 2019.

When was the latest funding round of QV Bioelectronics?

QV Bioelectronics' latest funding was a $***** Grant (prize money) round on Jan 21, 2026, with participation from 2 investors. Its primary sector is Neurology. In United Kingdom, the Neurology sector has seen $144M in funding in 2026 to date.

Where does QV Bioelectronics rank among its competitors?

QV Bioelectronics ranks 2nd amongst 21 active competitors, of which 6 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was QV Bioelectronics, which secured $6.05M in Jan, 2026.

Who are the top competitors of QV Bioelectronics?

QV Bioelectronics' top competitors include Novocure, ChemoTech and Autem Therapeutics. Among them, QV Bioelectronics secured the most recent funding round in January, 2026.

QV Bioelectronics - 2026 Company Profile, Team, Funding, Competitors & Financials

QV Bioelectronics is a series A company based in Manchester (United Kingdom), founded in 2019 by Christopher Bullock and Richard Fu. It operates as a Manufacturer of electrotherapy devices for treating brain tumors. QV Bioelectronics has raised $9.63M in funding from investors like SOSV, NIH and Catapult Ventures. The company has 21 active competitors, including 6 funded and 2 that have exited. Its top competitors include companies like Novocure, ChemoTech and Autem Therapeutics.

Company Details

Manufacturer of electrotherapy devices for treating brain tumors. The company's flagship product is GRACE, an implanted device that delivers electric field therapy directly to the tumour resection margins where GBM recurrence takes place.

Website: www.qvbio.co.uk/
Social
Email ID: *****@qvbio.co.uk
Registered Address: 1F70 MERESIDE,ALDERLEY PARK,NETHER ALDERLEY,CHESHIRE,ENGLAND,SK10 4TG

Key Metrics

Founded Year

2019

Location

Manchester, United Kingdom

Stage

Series A

Total Funding

$9.63M in 6 rounds

Latest Funding Round

Grant (prize money), Jan 21, 2026, $*****

Investors

SOSV & 19 more

Ranked

2^nd among 21 active competitors

Employee Count

18 as on Aug 31, 2026

Similar Companies

Novocure & 21 more

View QV Bioelectronics' full profile

QV Bioelectronics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Qv Bioelectronics Ltd. CIN: 11608210 , United Kingdom, Active	Oct 06, 2018	-	11 (As on Dec 31, 2024)
QV BIOELECTRONICS LTD CIN: 11608210 , United Kingdom, Active	Oct 06, 2018	-	6 (As on Nov 30, 2020)

QV Bioelectronics has raised a total funding of $9.63M over 6 rounds. Its first funding round was on Oct 29, 2019. Its latest funding round was a Grant (prize money) round on Jan 21, 2026 for $*****. 2 investors participated in its latest round. QV Bioelectronics has 13 institutional investors and 7 angel investors.

Here is the list of recent funding rounds of QV Bioelectronics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 21, 2026	1121506	Grant (prize money)	3742818	4338999	6687167	6996427
Jan 21, 2026	1037883	Series A	1816761	2069007	3275501	Empirical Ventures
Apr 03, 2023	4539684	Grant (prize money)	7647573	1714976	1845635	Ukri

Access funding benchmarks and valuations. Sign up today!

View details of QV Bioelectronics's funding rounds and investors

The founders of QV Bioelectronics are Christopher Bullock and Richard Fu. Christopher Bullock and Carl Daintree are the CEOs of QV Bioelectronics.

Here are the details of QV Bioelectronics' key team members:

Christopher Bullock: CEO & Co-Founder of QV Bioelectronics and founder of 1 other company.
Richard Fu: Co-Founder of QV Bioelectronics.
Contact Info: 1 email address
Carl Daintree: CEO of QV Bioelectronics.
Contact Info: 1 email address

View details of QV Bioelectronics's Founder profiles and Board Members

QV Bioelectronics' employee count trend

QV Bioelectronics has 18 employees as of Aug 26. Here is QV Bioelectronics's employee count trend over the years:

Employee count trend for QV Bioelectronics

Uncover QV Bioelectronics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of QV Bioelectronics include Novocure, ChemoTech and Autem Therapeutics. Here is the list of Top 10 competitors of QV Bioelectronics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Novocure 2000, Haifa (Israel), Public	Developer of therapeutics to treat solid tumours	$10M	Johnson & Johnson Innovation – JJDC, Pfizer Venture Investments ... & 13 others	63/100
2nd	QV Bioelectronics 2019, Manchester (United Kingdom), Series A	Manufacturer of electrotherapy devices for treating brain tumors	$9.63M	SOSV, Ukri & 18 others	53/100
3rd	ChemoTech 2015, Lund (Sweden), Public	Developer of electroporation devices for the treatment of cancer	-	EIC Fund, Europa	49/100
4th	Autem Therapeutics 2022, Hanover (United States), Series A	Developer of bioelectric technology-based device for cancer	$11.5M	Zentynel, Spectra Investments & 1 others	43/100
5th	SonALAsense 2019, Berkeley (United States), Series B	Developer of therapeutic solutions for treating cancer, neurological disorders & others	$13.7M	Keiretsu Forum, HHS & 1 others	41/100
6th	New Phase 2013, Petah Tikva (Israel), Funding Raised	Provider of nanoparticle based tumor-targeting molecules for cancer treatment	-	Real-Life Innovations	31/100
7th	LifeBridge Innovations 2016, Orlando (United States), Series A	Developer of electric connection-based device to treat human tissues and cure tumor-related diseases	$3.38M	-	29/100
8th	Gradient Medical 2020, Raleigh (United States), Funding Raised	Developer of pulsed electric field therapies for tumors	-	America’s Seed Fund, HHS	24/100
9th	LaZure Scientific 2006, Issaquah (United States), Deadpooled	Low dose alternating current to heat and preferentially destroy tumour cells	$5.16M	-	22/100
10th	CancerCell 2018, Los Angeles (United States), Seed	Developer of personalized bioelectric cancer tumor eradication therapy	-	Leonhardt Ventures	22/100